{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:21:52Z","timestamp":1723594912309},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.lungcan.2024.107891","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:22:35Z","timestamp":1720941755000},"page":"107891","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?"],"prefix":"10.1016","volume":"194","author":[{"given":"L.H.","family":"Douma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"de Gooijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107891_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-world efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: The meso-immune (GFPC04-2021) Trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer"},{"issue":"10272","key":"10.1016\/j.lungcan.2024.107891_b0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107891_b0015","first-page":"1743","article-title":"Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study","author":"Chow","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2024.107891_b0020","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.2217\/fon-2021-0047","article-title":"Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting","volume":"17","author":"Waterhouse","year":"2021","journal-title":"Future Oncol"},{"issue":"11, Supplement","key":"10.1016\/j.lungcan.2024.107891_b0025","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/j.jtho.2023.09.677","article-title":"P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)","volume":"18","author":"Aguirre","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"11, Supplement","key":"10.1016\/j.lungcan.2024.107891_b0030","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.jtho.2023.09.678","article-title":"P2.18-05 impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma: A real-world analysis","volume":"18","author":"Wu","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.lungcan.2024.107891_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8002","article-title":"BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014Results from the ETOP 13\u201318 trial","volume":"42","author":"Popat","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107891_b0040","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2024.107891_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107891_b0050","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2023.09.973","article-title":"2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107891_b0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224004252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:05:28Z","timestamp":1723586728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224004252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":11,"alternative-id":["S0169500224004252"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107891","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107866","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107891"}}